1. Volume 58, Issue 4, Pages 1613-1622 (October 2000)
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [3H]-SR  
Claudine Serradeil-Le Gal, Danielle Raufaste, Eléonore Double-Cazanave, Gilles Guillon, Corinne Garcia, Marc Pascal, Jean Pierre Maffrand 
Kidney International 
Volume 58, Issue 4, Pages (October 2000)
DOI: /j x
Copyright © 2000 International Society of Nephrology Terms and Conditions

2. Figure 1
Chemical structure of [3H]-SR The * indicates the position of tritium.
(Reproduced from the Journal of Clinical Investigation27, with permission from the American Society for Clinical Investigation.)
Kidney International  , DOI: ( /j x)
Copyright © 2000 International Society of Nephrology Terms and Conditions

3. Figure 2
Time–course of association (•) and dissociation (○) of [3H]-SR to membranes of Chinese hamster ovary (CHO) cells expressing the human renal arginine vasopressin (AVP) V2 receptors. Incubations were carried out as described in the Methods section in the presence of 2 nmol/L [3H]-SR for various periods of time. The arrow indicates time (45 min) at which unlabeled SR (1 μmol/L) was added to initiate the dissociation process. The results represent data from a typical experiment performed in duplicate and repeated three times without noticeable modifications.
Kidney International  , DOI: ( /j x)
Copyright © 2000 International Society of Nephrology Terms and Conditions

4. Figure 3
Saturation of [3H]-SR (•) and [3H]-AVP (▪) specific binding to membranes of CHO cells transfected with the human renal AVP V2 receptors. (A) Saturation isotherms. (B) Scatchard plots. Incubations were performed for 45 minutes at 25°C in the presence of 10 μg protein/mL and increasing concentrations of [3H]-SR or [3H]-AVP as described in the Methods section. Data are means calculated from a typical experiment performed in duplicate and repeated three times without noticeable changes.
Kidney International  , DOI: ( /j x)
Copyright © 2000 International Society of Nephrology Terms and Conditions

5. Figure 4
Inhibition of [3H]-SR specific binding to membranes of CHO cells expressing the human renal AVP V2 receptor by reference nonpeptide (A) and peptide (B) AVP/OT compounds. Incubations were carried out in the presence of 1.5 nmol/L [3H]-SR and increasing concentrations of the compound to be tested. Symbols in (A) for nonpeptide compounds: (○) SR ; (•) YM-087; (□) VPA 985; (▪) OPC-31260; (▾) SR 49059; (▿) OPC Symbols in (B) for peptide compounds: (▾) AVP; (○) dDAVP; (▪) d(CH2)5Tyr(Me)AVP; (•) SKF ; (□) d(CH2)5,D-lle2,lle4,Arg8]-AVP. Data are the means of a typical experiment performed in duplicate and repeated several times without noticeable changes.
Kidney International  , DOI: ( /j x)
Copyright © 2000 International Society of Nephrology Terms and Conditions

6. Figure 5
Labeling of AVP V2 receptors with [3H]-SR in human (A and B) and rat (C and D) kidney. Serial sections from frozen human samples dissected in the medullopapillary region and whole rat kidney were used. Autoradiograms were obtained by incubating adjacent kidney sections with 1.5 nmol/L [3H]-SR with (B and D; nonspecific binding) and without (A, B; total binding) cold SR (1 μmol/L). Calibration bars correspond to 2 mm.
Kidney International  , DOI: ( /j x)
Copyright © 2000 International Society of Nephrology Terms and Conditions